di-tert-butyl 2-((1,3-dioxoisoindolin-2-yl)methyl)-piperazine-1,4-dicarboxylate | 1256815-06-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: di-tert-butyl 2-((1,3-dioxoisoindolin-2-yl)methyl)-piperazine-1,4-dicarboxylate
• 英文别名: Di-tert-butyl 2-((1,3-dioxoisoindolin-2-yl)methyl)piperazine-1,4-dicarboxylate；ditert-butyl 2-[(1,3-dioxoisoindol-2-yl)methyl]piperazine-1,4-dicarboxylate
• CAS: 1256815-06-1
• 化学式: C₂₃H₃₁N₃O₆
• 分子量: 445.516
• InChiKey: LITNIKUYVXZSRX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  32
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  96.5
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  di-tert-butyl 2-((1,3-dioxoisoindolin-2-yl)methyl)-piperazine-1,4-dicarboxylate 在 盐酸 、 sodium hydride 、 甲胺 作用下， 以 四氢呋喃 、 乙醚 、 乙醇 、 二氯甲烷 、 mineral oil 为溶剂， 反应 4.0h， 生成 hexahydro-2-(3-cyanobenzyl)-imidazo[1,5-a]pyrazin-3-one
  参考文献：
  名称：

  新型2-取代咪唑并吡嗪酮衍生物的便捷合成

  摘要：

  摘要 以市售的哌嗪-2-羧酸为原料，制备了一系列新型的2-芳基和2-苄基取代的咪唑并吡嗪酮。通过简单的 Buchwald-Hartwig 偶联反应获得中间体 5a-g，并研究了催化剂、碱和溶剂对偶联反应的影响。偶联反应的最佳反应条件为PdCl2(dppf)/NaO-t-Bu/甲苯。图形概要

  DOI：

  10.1080/00397911.2010.525774
• 作为产物：
  描述：

  邻苯二甲酸亚胺 、 2-(羟甲基)-1,4-哌嗪二羧酸二叔丁酯 在 偶氮二甲酸二异丙酯 、 三苯基膦 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 以93%的产率得到di-tert-butyl 2-((1,3-dioxoisoindolin-2-yl)methyl)-piperazine-1,4-dicarboxylate
  参考文献：
  名称：

  新型2-取代咪唑并吡嗪酮衍生物的便捷合成

  摘要：

  摘要 以市售的哌嗪-2-羧酸为原料，制备了一系列新型的2-芳基和2-苄基取代的咪唑并吡嗪酮。通过简单的 Buchwald-Hartwig 偶联反应获得中间体 5a-g，并研究了催化剂、碱和溶剂对偶联反应的影响。偶联反应的最佳反应条件为PdCl2(dppf)/NaO-t-Bu/甲苯。图形概要

  DOI：

  10.1080/00397911.2010.525774

文献信息

• Metallo-beta-lactamase inhibitors
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10221163B2

  公开（公告）日：2019-03-05

  The present invention relates to metallo-beta-lactamase inhibitor compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein Z, RA, X1, X2 and R1 are as defined herein. The present invention also relates to compositions which comprise a metallo-beta-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta-lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more β-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance.

  本发明涉及式 I 的金属-β-内酰胺酶抑制剂化合物：及其药学上可接受的盐，其中 Z、RA、X1、X2 和 R1 如本文所定义。本发明还涉及组合物，其包含本发明的金属-β-内酰胺酶抑制剂化合物或其药学上可接受的盐，以及药学上可接受的载体，可选择与β-内酰胺抗生素和/或β-内酰胺酶抑制剂结合使用。本发明进一步涉及治疗细菌感染的方法，包括向患者施用治疗有效量的本发明化合物，与治疗有效量的一种或多种β-内酰胺类抗生素联合使用，也可选择与一种或多种β-内酰胺酶抑制剂化合物联合使用。本发明的化合物在本文所述的克服抗生素耐药性的方法中是有用的。
• Synthesis, biological assay in vitro and molecular docking studies of new imidazopyrazinone derivatives as potential dipeptidyl peptidase IV inhibitors
  作者：Yanyun Zhu、Shuang Xia、Mingjie Zhu、Weiyin Yi、Jiagao Cheng、Gonghua Song、Zhong Li、Peng Lu

  DOI：10.1016/j.ejmech.2010.08.002

  日期：2010.11

  A series of novel imidazopyrazinone derivatives were synthesized and evaluated with regard to their ability to inhibit dipeptidyl peptidase IV (DPP-IV) in vitro. Of these compounds (2R)-4-oxo-4-[2-(3-carbamoylbenzyl)-hexahydro-3-oxoimidazo [1,5-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine fumaric acid (17h, IC50 = 78 nM) was shown to effectively inhibit the activity of the dipeptidyl peptidase IV enzyme. Molecular docking studies were also performed to illustrate the binding mode of compounds 15c and 17h. Favorable interactions were identified from the binding of inhibitor 15c with DPP-IV. By analogy to the binding mode of compound 15c, it seems that the introduction of a substituted benzyl moiety onto the imidazopyrazinone could remarkably improve the inhibitory activity of compound 17h. (C) 2010 Elsevier Masson SAS. All rights reserved.
• 3-TETRAZOLYL-BENZENE-1,2-DISULFONAMIDE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP3313832B1

  公开（公告）日：2021-02-24
• METALLO-BETA-LACTAMASE INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20180244656A1

  公开（公告）日：2018-08-30

  The present invention relates to metallo-beta-lactamase inhibitor compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein Z, R A , X 1 , X 2 and R 1 are as defined herein. The present invention also relates to compositions which comprise a metallo-beta-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta-lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more β-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance.
• Convenient Synthesis of Novel 2-Substituted Imidazopyrazinone Derivatives
  作者：Yanyun Zhu、Gonghua Song、Peng Lu、Mingjie Zhu、Yilang Chen

  DOI：10.1080/00397911.2010.525774

  日期：2012.2.15

  Abstract Starting from commercially available piperazine-2-carboxylic acid, a series of novel 2-aryl and 2-benzyl substituted imidazopyrazinone were prepared. The intermediates 5a–g were obtained through facile Buchwald–Hartwig coupling reaction, and the effects of catalyst, base, and solvent on the coupling reaction were investigated. The optimal reaction conditions for the coupling reaction were

  摘要 以市售的哌嗪-2-羧酸为原料，制备了一系列新型的2-芳基和2-苄基取代的咪唑并吡嗪酮。通过简单的 Buchwald-Hartwig 偶联反应获得中间体 5a-g，并研究了催化剂、碱和溶剂对偶联反应的影响。偶联反应的最佳反应条件为PdCl2(dppf)/NaO-t-Bu/甲苯。图形概要